CHAMGAP
VERIFIEDPassed the Codex final verification and publication gate. Evidence-verification cutoff: 2026-07-11. AI was used for research and drafting; the existence of all 2 cited sources was verified at the original page, followed by blind grading, adversarial audit, and build validation. Methodology v1.0.
Verdict No. 261 · Search date 2026-07-11 · Methodology v1.0

Eyebright,
does it really help with Eye-fatigue relief and vision protection?

30-Second Summary
?
Evidence Grade ? · Safety unknown
Eyebright eye-drop research is not evidence for oral eye-fatigue or vision claims
What the
research shows
No human efficacy trial was identified that evaluated oral eyebright for eye fatigue or vision. Human studies mainly concern eyebright eye drops for conjunctivitis or ocular discharge in neonates and cannot be reinterpreted as evidence for an oral supplement.
What the
ads claim
Oral capsule advertising uses the plant's name and traditional ocular use to support phrases such as 'clear eyes,' 'vision support,' and 'eye-fatigue relief.' The identified clinical data are limited to a topical formulation and different conditions or symptoms.
*

Useful facts when choosing a product

  • Marketed oral capsules and the eye drops used in clinical studies have different administration routes.
  • The eye-drop evidence concerns conjunctivitis and ocular discharge, not vision protection.
  • Several related species may be sold under the commercial name Euphrasia officinalis, making botanical identification a variable.
  • A standardized oral dose and long-term safety profile have not been established.
ID

Chamgap Semantic Classification Code

Candidate index · review held

UNK.eyebright.UNK.eye-fatigue-relief-and-vision-protection.relieve.placebo

Unknown > Eyebright > Unknown > Eye-fatigue relief and vision protection > Symptom-relief claim > Placebo

An automated migration candidate, not an issued permanent code; exact claim scope remains under review. This machine-generated migration candidate helps retrieval but is not a permanent assignment. The original verdict ID and URL remain authoritative.

Download semantic index (JSON) · Codebook v1

Gap Measurement · Verdict 261 · ?
What advertising claims
What independent, higher-quality research supports
△ GAP
01

What the research actually shows

The Stoss 2000 study was an uncontrolled open cohort of 65 patients with conjunctivitis treated with eyebright eye drops. The Meier-Girard 2020 RCT gave eyebright eye drops or placebo for 96 hours to 84 preterm neonates with ocular discharge and found no significant difference in the primary outcome of discharge resolution without antibiotics. Neither study directly addresses oral efficacy for eye fatigue or vision.

02

Why this is classified as ?

Topical studies exist, but no human efficacy literature was identified for the oral ingredient-outcome pair of eye fatigue and vision protection; the grade is ? with no score.

Counterpoint. Traditional use and topical research provide a hypothesis. Absorption and ocular clinical effects from an oral supplement require separate testing.

Rejudgment record. New assessment — No oral monotherapy trial of eyebright for eye fatigue or vision protection; eye-drop studies mismatch the route and endpoints

✓

Cross-check — AI research and Codex final gate

AI was used for research and drafting. Blind grading, adversarial audit, and the methodology boundary rules were then reapplied before Codex performed the final evidence, grade, copy, and build checks. If a grade cannot be narrowed, both evidence positions and their reasons are published.
03

Evidence Table

StudyDesignSampleFundingEndpointResultWeight
Stoss M et al. 2000Multicenter prospective open-label single-arm cohort65UnknownRedness, swelling, discharge, burning, and foreign-body sensationMost participants improved after eye drops, but there was no control group and the route and target outcomes do not match the claim.Indirect
Meier-Girard D et al. 2020Randomized double-blind placebo-controlled trial84Swiss public and academic institutional supportResolution of ocular discharge by 96 hours without topical antibioticsEyebright eye drops did not significantly improve the primary treatment-success outcome versus placebo.Indirect
§

Receipt — 2 References

All 2 cited sources were verified for existence at the original page (as of 2026-07-11).

Stoss M, Michels C, Peter E, Beutke R, Gorter RW. Prospective Cohort Trial of Euphrasia Single-Dose Eye Drops in Conjunctivitis. J Altern Complement Med. 2000;6(6):499-508. DOI: 10.1089/acm.2000.6.499.
checked
Meier-Girard D, Gerstenberg G, Stoffel L, et al. Euphrasia Eye Drops in Preterm Neonates With Ocular Discharge: A Randomized Double-Blind Placebo-Controlled Trial. Front Pediatr. 2020;8:449. PMID: 32850558. DOI: 10.3389/fped.2020.00449.
checked
Research and draft: AI used · Cross-check: blind grading and adversarial audit
Final verification and publication gate: Codex · Evidence date: 2026-07-11 · Corrections: none
↗

Cite this verdict

Eyebright (Euphrasia officinalis) x eye-fatigue relief and vision protection Evidence Grade ? card
[Chamgap] Eyebright (Euphrasia officinalis) x eye-fatigue relief and vision protection — Evidence Grade ?. 2 cited sources checked. Source: https://chamgap.com/en/verdicts/eye/eyebright-eye-fatigue-vision/ · CC BY 4.0

CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.

!

What this document does and does not do

Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.
↑